Sean Kirk Net Worth

The estimated Net Worth of Sean Kirk is at least $1.06 Million dollars as of 6 April 2020. Mr. Kirk owns over 16,094 units of Emergent Biosolutions Inc stock worth over $95,162 and over the last 5 years he sold EBS stock worth over $965,640. In addition, he makes $0 as Executive Vice President und Manufacturing and Technical Operations at Emergent Biosolutions Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kirk EBS stock SEC Form 4 insiders trading

Sean has made over 1 trades of the Emergent Biosolutions Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 16,094 units of EBS stock worth $965,640 on 6 April 2020.

The largest trade he's ever made was selling 16,094 units of Emergent Biosolutions Inc stock on 6 April 2020 worth over $965,640. On average, Sean trades about 4,024 units every 0 days since 2020. As of 6 April 2020 he still owns at least 12,571 units of Emergent Biosolutions Inc stock.

You can see the complete history of Mr. Kirk stock trades at the bottom of the page.

Sean Kirk biography

Sean Kirk serves as Executive Vice President, Manufacturing and Technical Operations of the Company. Mr. Kirk joined us in 2003 and has served as executive vice president, manufacturing and technical operations since April 2019. Prior to this position, Mr. Kirk has held various senior leadership roles including senior vice president, manufacturing operations and contract development and manufacturing operations (CDMO) business unit lead from April 2017 to March 2019, senior vice president, biodefense operations from November 2015 to March 2017, senior vice president, biosciences operations from February 2014 to November 2015 and senior vice president, biodefense vaccines and therapeutics development from March 2012 to February 2014. Mr. Kirk also served in multiple roles of increasing responsibility at our manufacturing operations site in Lansing, Michigan. Before joining us, Mr. Kirk worked at Merial, a multinational animal health company, serving in various positions from 1996 to 2001. Mr. Kirk received both an M.B.A. and B.S. in Microbiology from the University of Georgia.

How old is Sean Kirk?

Sean Kirk is 45, he's been the Executive Vice President und Manufacturing and Technical Operations of Emergent Biosolutions Inc since 2019. There are 21 older and no younger executives at Emergent Biosolutions Inc. The oldest executive at Emergent Biosolutions Inc is Louis Sullivan, 86, who is the Independent Director.

What's Sean Kirk's mailing address?

Sean's mailing address filed with the SEC is 400 PROFESSIONAL DRIVE, SUITE 400, , GAITHERSBURG, MD, 20879.

Insiders trading at Emergent Biosolutions Inc

Over the last 18 years, insiders at Emergent Biosolutions Inc have traded over $131,382,266 worth of Emergent Biosolutions Inc stock and bought 4,647 units worth $138,981 . The most active insiders traders include Seamus Mulligan, Fuad El Hibri und Shahzad Malik. On average, Emergent Biosolutions Inc executives and independent directors trade stock every 21 days with the average trade being worth of $147,206. The most recent stock trade was executed by Kathryn C Zoon on 4 June 2024, trading 10,000 units of EBS stock currently worth $61,100.

What does Emergent Biosolutions Inc do?

emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent

Complete history of Mr. Kirk stock trades at Emergent Biosolutions Inc

Emergent Biosolutions Inc executives and stock owners

Emergent Biosolutions Inc executives and other stock owners filed with the SEC include:

• Robert Kramer,
  President, Chief Executive Officer, Director
• Fuad El-Hibri,
  Executive Chairman of the Board
• Robert G. Kramer,
  CEO, Pres & Exec. Director
• Richard Lindahl,
  Chief Financial Officer, Executive Vice President, Treasurer
• Atul Saran,
  Executive Vice President, Corporate Development, General Counsel and Corporate Secretary
• Adam Havey,
  Executive Vice President - Business Operations
• Fuad El-Hibri,
  Founder & Exec. Chairman
• Richard S. Lindahl,
  Exec. VP, CFO & Treasurer
• Adam R. Havey,
  Exec. VP & COO
• Atul Saran,
  Exec. VP of Corp. Devel. & Ext. Affairs and Gen. Counsel
• Seamus Mulligan,
  Director
• Ronald Richard,
  Lead Independent Director
• Zsolt Harsanyi,
  Independent Director
• Louis Sullivan,
  Independent Director
• Jerome Hauer,
  Independent Director
• George Joulwan,
  Independent Director
• Kathryn Zoon,
  Independent Director
• Sue Bailey,
  Independent Director
• Marvin White,
  Director
• Robert Burrows,
  Vice President, Investor Relations
• Sean Kirk,
  Executive Vice President, Manufacturing and Technical Operations
• Katherine Strei,
  Executive Vice President, Human Resources and Communications, Chief Human Resources Officer
• Katherine Strei,
  Exec. VP of HR & Chief HR Officer
• Nina DeLorenzo,
  Sr. VP of Global Communications & Public Affairs
• Lynn Kieffer,
  VP of Corp. Communications
• Howard Anderson,
  Sr. VP & Chief Information Officer
• Karen L. Smith,
  EVP, Chief Medical Officer
• John Niederhuber,
  Director
• Daniel Abdun Nabi,
  SVP Corp Aff, GC & Secretary
• L.L.C. Bio Pharm,,
  10% owner
• Stephen Lockhart,
  SVP Product Development
• L.L.C. Intervac,,
  10% owner
• Steven Chatfield,
  President, EPD UK & CSO
• R Don Elsey,
  VP Finance, CFO & Treasurer
• Barry Labinger,
  EVP, Biosciences Div.
• Denise Esposito,
  SVP Legal Affairs & GC
• L.L.C. Biologika,,
  
• Biologic Products, Inc. Mic...,
  
• Kyle Keese,
  SVP Mktg & Comm.
• Joe M Allbaugh,
  Director
• Mauro Gibellini,
  SVP Corporate Dev.
• Investments Ltd Microscience,
  10% owner
• Shahzad Malik,
  Director
• Edward Arcuri,
  EVP & COO
• Thomas Zink,
  SVP & CMO
• Robert Calvin Myers,
  
• Joseph C Papa,
  President and CEO
• Jennifer Lynne Fox,
  EVP, Ext Aff, GC, Corp Sec
• Keith Katkin,
  Director
• Coleen Glessner,
  EVP, Quality & Ethics, and CPL
• Sujata Tyagi Dayal,
  Director
• Paul Anthony Williams,
  SVP, Products Business
• William Hartzel,
  SVP, Bioservices
• Neal Franklin Fowler,
  Director
• Donald W De Golyer,
  Director